SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(RULE 13d - 102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No.)*

Sucampo Pharmaceuticals, Inc.

(Name of Issuer)

Class A Common Stock, par value \$0.01 (Title of Class of Securities)

864909106 (CUSIP Number)

December 6, 2017 (Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)
☐ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on the Following Pages) (Page 1 of 11 Pages)

CUSIP No. 864909106 Page 2 c				Page 2 of 11	
1.	NAMES OF REPORTING PERSONS				
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)					
	Linden C	tal L.P.			
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) □ (b) □				
3.	SEC USE ONLY				
4.	CITIZENSHIP OR PLACE OF ORGANIZATION				
	Bermuda				
		5.	SOLE VOTING POWER		
NUM	IBER OF		0		
SHARES		6.	SHARED VOTING POWER		
BENEFICIALLY OWNED BY			2,489,131		
EACH REPORTING		7.	SOLE DISPOSITIVE POWER		
PERSON			0		
WITH:		8.	SHARED DISPOSITIVE POWER		
			2,489,131		
9.	AGGRE	GAT	TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	2,489,132	1			
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*				

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

PN

11.

12.

^{*} SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP N	To. 8649091	.06		Page 3 of 11	
1.	NAMES OF REPORTING PERSONS				
	I.R.S. IDI	ENT	CIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)		
	Linden A	dvis	sors LP		
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*				
	(a) ⊠	(b			
	OF CHICE				
3.	SEC USE	, Or	NLY		
4.	CITIZEN	SHI	IP OR PLACE OF ORGANIZATION		
	OIIILLI.	011			
	Delaware				
		5.	SOLE VOTING POWER		
	IBER OF	6.	0 SHARED VOTING POWER		
	IARES FICIALLY	0.	SHARED VOTING FOWER		
	NED BY		2,489,131		
	ACH	7.	SOLE DISPOSITIVE POWER		
REPORTING					
PERSON WITH:		_			
*	, 1111.	8.	SHARED DISPOSITIVE POWER		
			2,489,131		
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	2 400 121				
10.	2,489,131		X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*		
10.	CHECK	JU2	III THE AGGREGATE AMOUNT IN KOW (3) EXCLUDES CERTAIN SHAKES.		
	П				

11.

12.

5.1%

IA, PN

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

^{*} SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 864909106 Page 4 of 1					
1.	NAMES OF REPORTING PERSONS				
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	Linden G	P L	LC		
2.	2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*				
	(a) ⊠	(b) [[]		
3.	SEC USE	E OI	NLY		
4.	CITIZENSHIP OR PLACE OF ORGANIZATION				
	Delaware				
		5.	SOLE VOTING POWER		
NUMBER OF			0		
	ARES	6.	SHARED VOTING POWER		
BENEFICIALLY OWNED BY			2,489,131		
EACH		7.	SOLE DISPOSITIVE POWER		
REPORTING					
PERSON WITH:		0	0		
	1111.	8.	SHARED DISPOSITIVE POWER		
			2,489,131		
9.	9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	2,489,131				
10.	CHECK	BO	X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*		
11	DEDCENT OF CLASS DEDDESENTED BY AMOUNT IN DOW (0)				

5.1%

HC

12.

^{*} SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP N	o. 864909	106		Page 5 of 11	
1.	NAMES OF REPORTING PERSONS				
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	Siu Min	Won	g		
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) □ (b) □				
3.	SEC USI	E OI	ILY		
4.	CITIZEN	ISH	IP OR PLACE OF ORGANIZATION		
	China and USA				
		5.	SOLE VOTING POWER		
NUMBER OF		6	0		
	ARES FICIALLY	6.	SHARED VOTING POWER		
	NED BY		2,489,131		
	ACH	7.	SOLE DISPOSITIVE POWER		
PE	ORTING RSON		0		
WITH:		8.	SHARED DISPOSITIVE POWER		
			2,489,131		
9.	AGGRE	GAT	E AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	2,489,131				
10.	CHECK	BO	X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*		
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				

5.1%

IN, HC

12.

^{*} SEE INSTRUCTIONS BEFORE FILLING OUT!

ITEM 1(a). Name of Issuer:

Sucampo Pharmaceuticals, Inc. (the "Issuer").

Item 1(b). Address of Issuer's Principal Executive Offices:

805 King Farm Boulevard, Suite 550 Rockville, MD 20850

Item 2(a). Name of Persons Filing:

The names of the persons filing this statement on Schedule 13G are: Linden Capital L.P., a Bermuda limited partnership ("Linden Capital"), Linden Advisors LP, a Delaware limited partnership ("Linden Advisors"), Linden GP LLC, a Delaware limited liability company ("Linden GP"), and Siu Min (Joe) Wong ("Mr. Wong," and collectively, the "Reporting Persons"). Linden Advisors is the investment manager of Linden Capital, Linden GP is the general partner of Linden Capital, and Mr. Wong is the principal owner and controlling person of Linden Advisors and Linden GP. Therefore, Linden Advisors, Linden GP and Mr. Wong may each be deemed to beneficially own the Common Shares (as defined below) owned by Linden Capital.

Item 2(b). Address of Principal Business Office or, if None, Residence:

The principal business address for Linden Capital is Victoria Place, 31 Victoria Street, Hamilton HM10, Bermuda.

The principal business address for each of Linden Advisors, Linden GP and Mr. Wong is 590 Madison Avenue, 15th Floor, New York, New York 10022.

Item 2(c). Citizenship:

Linden Capital is a Bermuda limited partnership.

Linden Advisors is a Delaware limited partnership.

Linden GP is a Delaware limited liability company.

Mr. Wong is a citizen of China and the United States.

Item 2(d). Title of Class of Securities

Class A Common Stock, par value \$0.01 (the "Common Shares").

Item 2(e). CUSIP Number: 8649091	.06
----------------------------------	-----

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: Not applicable.

(a)	Broker or dealer registered under Section 15 of the Exchange Act.
(b)	Bank as defined in Section 3(a)(6) of the Exchange Act.
(c)	Insurance company defined in Section 3(a)(19) of the Exchange Act

(d)	Investment company registered under Section 8 of the Investment Company Act.
(e)	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
(f)	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
(g)	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
(h)	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i)	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
(j)	Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

The Reporting Persons collectively beneficially own 2,489,131 Common Shares as a result of Linden Capital's ownership of the Issuer's 3.25% Convertible Senior Notes due 2021.

(b) Percent of class

The Reporting Persons have beneficial ownership of Common Shares constituting 5.1% of the outstanding Common Shares.

- (c) Number of shares as to which such person has:
 - (i) Sole power to vote or to direct the vote

Not applicable.

(ii) Shared power to vote or to direct the vote

Linden Capital, Linden Advisors, Linden GP and Mr. Wong have shared power to vote or direct the vote of the 2,489,131 Common Shares beneficially owned by Linden Capital.

(iii) Sole power to dispose or to direct the disposition of

Not applicable.

(iv) Shared power to dispose or to direct the disposition of

Linden Capital, Linden Advisors, Linden GP and Mr. Wong have shared power to dispose or direct the disposition of the 2,489,131 Common Shares beneficially owned by Linden Capital.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit B attached hereto.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below, the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Sec. 240.14a-11.

SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

Dated: December 8, 2017

LINDEN CAPITAL L.P.

By: Linden GP LLC, its general partner

By: <u>/s/ Saul Ahn</u>
Saul Ahn,
Authorized Signatory

LINDEN ADVISORS LP

By: <u>/s/ Saul Ahn</u>
Saul Ahn,
General Counsel

LINDEN GP LLC

By: <u>/s/ Saul Ahn</u>
Saul Ahn,
Authorized Signatory

/s/ Siu Min Wong

SIU MIN WONG

EXHIBIT A JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Shares of Sucampo Pharmaceuticals, Inc. dated December 6, 2017 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

Dated: December 7, 2017

LINDEN CAPITAL L.P.

By: Linden GP LLC, its general partner

By: <u>/s/ Saul Ahn</u>
Saul Ahn,
Authorized Signatory

LINDEN ADVISORS LP

By: /s/ Saul Ahn

Saul Ahn, General Counsel

LINDEN GP LLC

By: /s/ Saul Ahn

Saul Ahn, Authorized Signatory

/s/ Siu Min Wong

SIU MIN WONG

EXHIBIT B IDENTIFICATION OF MEMBERS OF THE GROUP

Linden Capital L.P. Linden Advisors LP Linden GP LLC Siu Min Wong